7/16
08:30 am
vivs
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
High
Report
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
7/16
02:48 am
vivs
Eli Lilly Milestone and Triple-Digit Growth Outlook Put This Microcap in Focus [Globe and Mail, The (Toronto, Canada)]
High
Report
Eli Lilly Milestone and Triple-Digit Growth Outlook Put This Microcap in Focus [Globe and Mail, The (Toronto, Canada)]
7/15
08:05 am
vivs
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
Medium
Report
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
6/29
08:05 am
vivs
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
Neutral
Report
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
5/23
06:02 pm
vivs
VivoSim Labs (VIVS) was downgraded by
Weiss Ratings from "sell (d-)" to "sell (e+)".
Medium
Report
VivoSim Labs (VIVS) was downgraded by
Weiss Ratings from "sell (d-)" to "sell (e+)".
5/8
06:03 pm
vivs
VivoSim Labs (VIVS) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
Low
Report
VivoSim Labs (VIVS) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
4/28
08:05 am
vivs
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
Medium
Report
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing